Filtered By:
Cancer: Prostate Cancer
This page shows you your search results in order of date. This is page number 18.
Order by Relevance | Date
Total 25934 results found since Jan 2013.
A meta-analysis of epitopes in prostate-specific antigens identifies opportunities and knowledge gaps
CONCLUSION: CEDAR provides a comprehensive repository of epitopes related to prostate-specific antigens. This inventory of epitope data with its wealth of searchable T cell, B cell and MHC ligand information provides a useful tool for the scientific community. At the same time, we identify significant knowledge gaps that could be addressed by experimental analysis.PMID:37679223 | DOI:10.1016/j.humimm.2023.08.145
Source: Human Immunology - September 7, 2023 Category: Allergy & Immunology Authors: Gabriele Foos Nina Blazeska Morten Nielsen Hannah Carter Zeynep Kosaloglu-Yalcin Bjoern Peters Alessandro Sette Source Type: research
Symptom Experiences Among Individuals With Prostate Cancer and Their Partners: Influence of Sociodemographic and Cancer Characteristics
Oncol Nurs Forum. 2023 Feb 17;50(2):230-240. doi: 10.1188/23.ONF.230-240.ABSTRACTOBJECTIVES: To determine if subgroups of individuals with prostate cancer and their partners could be identified based on their distinct symptom profiles and to identify and characterize subgroups based on sociodemographic and cancer characteristics.SAMPLE & SETTING: 263 individuals with prostate cancer and 263 partners recruited from three academic cancer centers in the Midwest.METHODS & VARIABLES: Latent class analysis was applied to divide individuals into subgroups based on symptom prevalence. Multinomial logistic regression models...
Source: Oncology Nursing Forum - September 7, 2023 Category: Nursing Authors: Shenmeng Xu Xianming Tan Peiran Guo Chunxuan Ma Katrina R Ellis Angela B Smith Laurel Northouse Lixin Song Source Type: research
Effects of Web-Based and Mobile Self-Care Support in Addition to Standard Care in Patients After Radical Prostatectomy: Randomized Controlled Trial
CONCLUSIONS: ePATH did not affect postoperative side effects or self-care but reflected how this support may work in typical clinical conditions. To complement standard rehabilitation, digital self-care support must be adapted to the context and individual preferences for use and effect.TRIAL REGISTRATION: ISRCTN Registry ISRCTN18055968; https://www.isrctn.com/ISRCTN18055968.INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): RR2-10.2196/11625.PMID:37672332 | DOI:10.2196/44320
Source: Cancer Control - September 6, 2023 Category: Cancer & Oncology Authors: Camilla Wennerberg Amanda Hellstr öm Kristina Schildmeijer Mirjam Ekstedt Source Type: research
Reirradiation salvage radiotherapy for recurrent prostate cancer after primary low-dose brachytherapy
CONCLUSIONS: Our data suggest that the treatment of locally recurrent prostate cancer with S-EBRT could provide adequate disease control safely and be used as an additional treatment in the natural history of prostate cancer patients. However, the results are still early and the sample is small; larger studies with longer follow-up would be mandatory.PMID:37672205 | DOI:10.1007/s12094-023-03315-1
Source: Clinical Prostate Cancer - September 6, 2023 Category: Cancer & Oncology Authors: Óscar Muñoz Muñoz El ías Gomis Sellés Blas David Delgado Le ón Juan Carlos Mateos Perez Montserrat Baeza Trujillo Maria Perucha Ortega Jos é Luis López Guerra Patricia Cabrera Rold án Source Type: research
ZMYND10 could serve as a prognostic biomarker for patients with prostate cancer
Asian J Surg. 2023 Sep 4:S1015-9584(23)01105-3. doi: 10.1016/j.asjsur.2023.07.093. Online ahead of print.NO ABSTRACTPMID:37673741 | DOI:10.1016/j.asjsur.2023.07.093
Source: Asian Journal of Surgery - September 6, 2023 Category: Surgery Authors: Jie Wang Yuhan Xiao Dengxiong Li Chi Zhang Source Type: research
KRT72 might serves as a prognostic biomarker for patients with prostate cancer
Asian J Surg. 2023 Sep 4:S1015-9584(23)01107-7. doi: 10.1016/j.asjsur.2023.07.097. Online ahead of print.NO ABSTRACTPMID:37673738 | DOI:10.1016/j.asjsur.2023.07.097
Source: Asian Journal of Surgery - September 6, 2023 Category: Surgery Authors: Jie Wang Yuhan Xiao Qingxin Yu Chi Zhang Source Type: research
Discovery of novel flavonoid-based CDK9 degraders for prostate cancer treatment via a PROTAC strategy
In this study, the PROTAC strategy was used to perform structural modifications of the flavonoid derivative LWT-111 to design a series of flavonoid-based CDK9 degraders. Notably, compound CP-07 emerged as a potent CDK9 degrader, effectively suppressing the proliferation and colony formation of 22RV1 cells by downregulating Mcl-1 and c-Myc. Moreover, CP-07 exhibited significant tumor growth inhibition with a TGI of 75.1% when administered at a dose of 20 mg/kg in the 22RV1 xenograft tumor model. These findings demonstrated the potential of CP-07 as a powerful flavonoid-based CDK9 degrader for prostate cancer therapy.PMID:37...
Source: European Journal of Medicinal Chemistry - September 6, 2023 Category: Chemistry Authors: Tizhi Wu Zhiming Zhang Guangyue Gong Zekun Du Yifan Xu Sixian Yu Feihai Ma Xuan Zhang Yuxiao Wang Haoming Chen Shiqi Wu Xi Xu Zhixia Qiu Zhiyu Li Hongxi Wu Jinlei Bian Jubo Wang Source Type: research
ZMYND10 could serve as a prognostic biomarker for patients with prostate cancer
Asian J Surg. 2023 Sep 4:S1015-9584(23)01105-3. doi: 10.1016/j.asjsur.2023.07.093. Online ahead of print.NO ABSTRACTPMID:37673741 | DOI:10.1016/j.asjsur.2023.07.093
Source: Asian Journal of Surgery - September 6, 2023 Category: Surgery Authors: Jie Wang Yuhan Xiao Dengxiong Li Chi Zhang Source Type: research
KRT72 might serves as a prognostic biomarker for patients with prostate cancer
Asian J Surg. 2023 Sep 4:S1015-9584(23)01107-7. doi: 10.1016/j.asjsur.2023.07.097. Online ahead of print.NO ABSTRACTPMID:37673738 | DOI:10.1016/j.asjsur.2023.07.097
Source: Asian Journal of Surgery - September 6, 2023 Category: Surgery Authors: Jie Wang Yuhan Xiao Qingxin Yu Chi Zhang Source Type: research
Reirradiation salvage radiotherapy for recurrent prostate cancer after primary low-dose brachytherapy
CONCLUSIONS: Our data suggest that the treatment of locally recurrent prostate cancer with S-EBRT could provide adequate disease control safely and be used as an additional treatment in the natural history of prostate cancer patients. However, the results are still early and the sample is small; larger studies with longer follow-up would be mandatory.PMID:37672205 | DOI:10.1007/s12094-023-03315-1
Source: Clinical Prostate Cancer - September 6, 2023 Category: Cancer & Oncology Authors: Óscar Muñoz Muñoz El ías Gomis Sellés Blas David Delgado Le ón Juan Carlos Mateos Perez Montserrat Baeza Trujillo Maria Perucha Ortega Jos é Luis López Guerra Patricia Cabrera Rold án Source Type: research
A prospective, multicenter study on the clinical effectiveness of abiraterone in metastatic castration-resistant prostate cancer in Korea: Pre- vs. post-chemotherapy
CONCLUSIONS: In this postmarketing surveillance, AAP benefited patients with mCRPC, especially in settings before chemotherapy was administered, resulting in a high PSA response and longer PSA and radiologic progression-free survival with tolerable adverse drug reactions.PMID:37668202 | DOI:10.4111/icu.20230128
Source: Cancer Control - September 5, 2023 Category: Cancer & Oncology Authors: Seung-Hwan Jeong Sang Eun Yeon Su Youn Kim Tae Gyun Kwon Seong Soo Jeon Young Deuk Choi Dongdeuk Kwon Byung Ha Chung Sung-Hoo Hong Byung Hoon Kim Hyo Jin Lee Sang Joon Shin Woo Suk Choi Sung Woo Park Taek Won Kang Seok Joong Yun Jin Seon Cho See Min Choi Source Type: research
Corrigendum: Correction of the Figure. Trends of stratified prostate cancer risk in a single Korean province from 2003 to 2021: A multicenter study conducted using regional training hospital data
Investig Clin Urol. 2023 Sep;64(5):514-516. doi: 10.4111/icu.20220317c.ABSTRACTThis corrects the article on p. 140 in vol. 64, PMID: 36882172.PMID:37668210 | DOI:10.4111/icu.20220317c
Source: Clinical Prostate Cancer - September 5, 2023 Category: Cancer & Oncology Authors: Young Hwii Ko Byung Hoon Kim Se Yun Kwon Hyun Jin Jung Yoon Soo Hah Yeon-Joo Kim Hyun Tae Kim Jun Nyung Lee Jeong Hyun Kim Tae-Hwan Kim Daegu-Kyungbook Urologic Oncology Study Group Source Type: research
A prospective, multicenter study on the clinical effectiveness of abiraterone in metastatic castration-resistant prostate cancer in Korea: Pre- vs. post-chemotherapy
CONCLUSIONS: In this postmarketing surveillance, AAP benefited patients with mCRPC, especially in settings before chemotherapy was administered, resulting in a high PSA response and longer PSA and radiologic progression-free survival with tolerable adverse drug reactions.PMID:37668202 | DOI:10.4111/icu.20230128
Source: Clinical Prostate Cancer - September 5, 2023 Category: Cancer & Oncology Authors: Seung-Hwan Jeong Sang Eun Yeon Su Youn Kim Tae Gyun Kwon Seong Soo Jeon Young Deuk Choi Dongdeuk Kwon Byung Ha Chung Sung-Hoo Hong Byung Hoon Kim Hyo Jin Lee Sang Joon Shin Woo Suk Choi Sung Woo Park Taek Won Kang Seok Joong Yun Jin Seon Cho See Min Choi Source Type: research
Prostate-specific antigen screening for prostate cancer: An old but never-ending story
Investig Clin Urol. 2023 Sep;64(5):422-424. doi: 10.4111/icu.20230229.NO ABSTRACTPMID:37668197 | DOI:10.4111/icu.20230229
Source: Clinical Prostate Cancer - September 5, 2023 Category: Cancer & Oncology Authors: Sun Il Kim Source Type: research
Poly (ADP-ribose) polymerase inhibitor: A new horizon in advanced prostate cancer treatment
Investig Clin Urol. 2023 Sep;64(5):419-421. doi: 10.4111/icu.20230185.NO ABSTRACTPMID:37668196 | DOI:10.4111/icu.20230185
Source: Clinical Prostate Cancer - September 5, 2023 Category: Cancer & Oncology Authors: Minyong Kang Seong Soo Jeon Source Type: research
